MVA R&D Network meeting

Welcome to Medicon Valley Alliance R&D Network and our 3rd meeting!

What can R&D learn from orphan drug development:
– The use of AI to find the right patients
– Working closely with stakeholders

Finding the right treatment for the right patient is one major challenge within R&D. The challenges inherent in drug development in rare diseases has enforced stakeholders in this field in pioneering new ways during their R&D.

Medicon Valley Alliance, together with one of our members – Zealand Pharma – welcomes you to the MVA R&D Network and our 3rd meeting where we will discuss lessons learned from drug development in rare diseases and how this could be applied to all drug development. Aspects like how to implement AI and how to relate to and interact with the ever-changing stakeholder landscape will be highlighted.

Sign up

The network
Medicon Valley Alliance R&D Network – an interdisciplinary network for C-level R&D executives (CSOs, CMOs, VPs), university professors and PIs, and top-level managers in the hospital sector. The objective of the network is to strengthen collaboration and knowledge-sharing to stimulate that great science turns into successful innovations for the benefit of patients and society. The network is scheduled to meet twice a year.
The network is free of charge and is limited to Medicon Valley Alliance members. Non-member organizations and companies are welcome to attend one network event to evaluate whether joining the network is relevant. If so, becoming a member of Medicon Valley Alliance will automatically allow you to join the Medicon Valley Alliance R&D Network.

Program
Moderator: Anders Hinsby, CEO, Orphazyme

17.00 – 17.30	Registration, networking and a bite to eat
17.30 – 17.40	Welcome  Petter Hartman, CEO, Medicon Valley Alliance Camilla Westergaard Borgen, Commercial Development Director, Zealand Pharma A/S
17.40-18.25	The use of AI to find the right patients
17.40	Deploying predictive analytics for precision patient and provider finding Oodaye Shukla, Chief Data & Analytics Officer, HVH Precision Analytics, Pennsylvania, US
18.10	AI at Lund University – ongoing activities and opportunities for academia-industry interaction Sonja Aits, Associate Senior Lecturer, Cell Death and Lysosomes Group, Dept. of Experimental Medical Science, Lund University
18.25-19.05	Working closely with stakeholders
18.25	Early engagement with regulators to improve drug development Steffen Thirstrup, Director, NDA Regulatory Advisory Board, former CHMP member and Division Head at the Danish Medicines Agency
18.45	Why involve patients in medical research?  Jeanette Andersen, EUPATI Patient Expert & Chair, Lupus Europe
19.05-19.25	Panel discussion Oodaye Shukla, Chief Data & Analytics Officer, HVH Precision Analytics, Pennsylvania, US Sonja Aits, Associate Senior Lecturer, Cell Death and Lysosomes Group, Dept. of Experimental Medical Science, Lund University Steffen Thirstrup, Director, NDA Regulatory Advisory Board, former CHMP member and Division Head at the Danish Medicines Agency Jeanette Andersen, EUPATI Patient Expert & Chair,Lupus Europe
19.25-19.30	Concluding remarks Camilla Westergaard Borgen, Commercial Development Director Zealand Pharma A/S
19.30 – 20.00	Networking & refreshments

For more information please contact Senior Project Manager Helen Pettersson: hp@mva.org

Host	Sponsors

MVA R&D Network is managed by	In collaboration with